Miniaturized CGM Patent Snapshot in 2026
The patent corpus for miniaturized continuous glucose monitoring captured by this search is extremely small, comprising only 2 patent families, with all activity concentrated in 2025 and split between Indian and US jurisdictions. At this corpus size, no statistically meaningful concentration or trend conclusions can be drawn; the evidence is better read as a signal that the search scope may need broadening or that the field’s dominant prior art sits outside the current query boundary.
Four individual filers share a near-empty corpus — competitive structure is not yet discernible
The applicant ranking lists four filers — David Stephen J B, Mohana Priyan K, UXN, and Sreeja B S — each holding one patent record, with David Stephen J B ranked first on that basis.
The top five filers account for 100% of the ranked applicants visible in this query’ combined total, which is an artifact of the corpus containing only two patent families. No tier gap or concentration pattern can be inferred from data this sparse.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | DAVID STEPHEN J B | 1 | |
| 2 | MOHANA PRIYAN K | 1 | |
| 3 | UXN | 1 | |
| 4 | SREEJA B S | 1 |
The joint presence of individual inventors alongside UXN suggests early-stage, small-team development rather than an established industrial R&D ecosystem. No large corporate assignee appears in the evidence.
The most recent filing period (2024–2025) is subject to publication lag, meaning additional applications filed in that window may not yet be visible in this corpus. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
All filing activity is concentrated in 2025; technology focus is diagnosis and fluid-delivery devices
The annual trend and technology-composition charts reflect a corpus of only 2 patent families, so both should be read as descriptive snapshots rather than trend signals.
Annual filing trend
Zero activity is recorded from 2017 through 2024; both patent families appear in 2025. Given publication lag, any interpretation of this as a sudden surge rather than a data artifact requires caution. The 2026 count of zero is expected given lag.
↗ Hover for values · click a bar to ask EurekaTechnology composition
Both records fall under A61B (Diagnosis and surgery), and one also carries an A61M (Devices for body fluids) classification. This dual-class presence is consistent with a wearable CGM device that integrates sensing and fluid-interface functions.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Implantable continuous glucose monitor device
A continuous glucose monitor (CGM) sensor includes a glucose oxidation electrode and a counter electrode, and does not include a glucose-specific enzyme. The glucose oxidation electrode includes a nanoporous layer comprising metal nanoparticles. The CGM sensor generates an electrical signal indicative glucose oxidation in a liquid containing glucose, which… (excerpt from the patent abstract)
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
Assignee snapshot from the current evidence set
The applicants below are visible in this query result. Because the evidence set is relatively small, read this section as a directional snapshot rather than a full competitive ranking.
David Stephen J B
David Stephen J B holds 1 patent record and is ranked first among the four filers. Technology emphasis spans both A61B (Diagnosis and surgery) and A61M (Devices for body fluids), consistent with an integrated CGM device approach. No momentum trend data is available given the single-year filing window.
patent records: 1UXN
UXN is the only corporate entity in the ranking, holding 1 patent record focused on A61B (Diagnosis and surgery). Its presence alongside individual inventors suggests an early-stage commercial interest. No prior-period filings are recorded, so trajectory cannot be assessed.
patent records: 1Frequently asked questions
The current evidence covers 2 patent families. This is a very small corpus, and engineers should treat findings as preliminary until a broader search is conducted.
Four applicants each hold one patent record: David Stephen J B (ranked first), Mohana Priyan K, UXN, and Sreeja B S. UXN is the only corporate entity; the others are individual inventors.
One patent record is filed in India and one in the United States. No other jurisdictions appear in the evidence. India is recorded as the lead office.
Both records carry A61B (Diagnosis and surgery) classifications, and one also carries A61M (Devices for body fluids). Notably absent are biosensor chemistry (G01N) and wireless communication (H04W, H04L) branches that typically appear in commercial CGM patent portfolios.
All recorded activity is concentrated in 2025; years 2017 through 2024 show zero filings in this corpus. Given publication lag, the 2025 figure may not yet be complete and 2026 data is expected to remain low until more applications publish.
The evidence references two patent documents: US12629065B1 and IN202541091803A. Metadata such as title, assignee, and detailed claims were not returned in the evidence set and should be reviewed directly in a patent database.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.